Search - tctmd.com

Displaying 1 - 20 of 26

Sort: Relevancy | Date

$Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC$

News Conference News ACC 2024

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Michael O'Riordan

April 08, 2024

$Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC)$

Presentation ACC 2024

Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC)

Presenter: Rasha K. Al-Lamee

April 08, 2024

News Conference News ACC 2024

Icosapent Ethyl Lowers CV Risk Across Lp(a) Range: REDUCE-IT

Todd Neale

March 27, 2024

News Conference News ACC 2023

Short DAPT Noninferior to 1 Year After Ultrathin DES PCI: HOST-IDEA

Yael L. Maxwell

March 09, 2023

News Conference News ACC 2023

No Downside to Immediate Complete Revascularization in ACS: BIOVASC

Michael O'Riordan

March 06, 2023

News Conference News ACC 2023

Stable CAD Plaque Morphology Improved by PCSK9 Inhibitors: YELLOW III

Shelley Wood

March 04, 2023

News Conference News ACC 2022

No Difference in 1-Year QoL Between FFR-Guided PCI and CABG: FAME-3

Michael O'Riordan

April 13, 2022

News Conference News ACC 2022

FLAVOUR: FFR as Good as IVUS for Intermediate Coronary Stenoses

Michael O'Riordan

April 06, 2022

News Conference News ACC 2022

In ANOCA, Diltiazem Fails to Improve Vasomotor Function: EDIT-CMD

Caitlin E. Cox

April 02, 2022

News Conference News ACC 2021

Complete Revascularization Analysis of ISCHEMIA Opens ‘Pandora’s Box’

Michael O'Riordan

May 18, 2021

News Conference News ACC 2021

Clopidogrel, Not Aspirin, for Post-DAPT Monotherapy After PCI: HOST-EXAM

L.A. McKeown

May 16, 2021

News Conference News ACC 2020

Icosapent Ethyl’s CV Benefit Closely Tied to Serum EPA Levels: REDUCE-IT

Todd Neale

April 02, 2020

News Conference News ACC 2020

Anatomic Burden, Ischemia Severity, and Outcomes in ISCHEMIA

Shelley Wood

March 29, 2020

News Conference News ACC 2020

Colchicine Cost-effective in Canada, and Even in the US: COLCOT

Caitlin E. Cox

March 28, 2020

News Conference News ACC 2020

More Symptoms, Less Extensive Disease in Women With Stable CAD: ISCHEMIA

Michael O'Riordan

March 28, 2020

News Conference News ACC 2019

Modest LDL Cholesterol Reduction With Bempedoic Acid in Among High-Risk Patients: CLEAR Wisdom

Michael O'Riordan

March 20, 2019

News Conference News ACC 2018

High CRP Linked to Bigger Absolute Drops in CV Events for Patients Taking Evolocumab

Michael O'Riordan

March 20, 2018

News Conference News ACC 2018

Too Soon for 6-Month DAPT, Say SMART-DATE Investigators, Despite Positive Trial

Yael L. Maxwell

March 12, 2018

News Conference News ACC 2018

ACC 2018, Day One: Live From Orlando! The ODYSSEY Begins

Shelley Wood

March 10, 2018

News Conference News ACC 2018

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

Shelley Wood

March 05, 2018

Advertisement

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC)

Icosapent Ethyl Lowers CV Risk Across Lp(a) Range: REDUCE-IT

Short DAPT Noninferior to 1 Year After Ultrathin DES PCI: HOST-IDEA

No Downside to Immediate Complete Revascularization in ACS: BIOVASC

Stable CAD Plaque Morphology Improved by PCSK9 Inhibitors: YELLOW III

No Difference in 1-Year QoL Between FFR-Guided PCI and CABG: FAME-3

FLAVOUR: FFR as Good as IVUS for Intermediate Coronary Stenoses

In ANOCA, Diltiazem Fails to Improve Vasomotor Function: EDIT-CMD

Complete Revascularization Analysis of ISCHEMIA Opens ‘Pandora’s Box’

Clopidogrel, Not Aspirin, for Post-DAPT Monotherapy After PCI: HOST-EXAM

Icosapent Ethyl’s CV Benefit Closely Tied to Serum EPA Levels: REDUCE-IT

Anatomic Burden, Ischemia Severity, and Outcomes in ISCHEMIA

Colchicine Cost-effective in Canada, and Even in the US: COLCOT

More Symptoms, Less Extensive Disease in Women With Stable CAD: ISCHEMIA

Modest LDL Cholesterol Reduction With Bempedoic Acid in Among High-Risk Patients: CLEAR Wisdom

High CRP Linked to Bigger Absolute Drops in CV Events for Patients Taking Evolocumab

Too Soon for 6-Month DAPT, Say SMART-DATE Investigators, Despite Positive Trial

ACC 2018, Day One: Live From Orlando! The ODYSSEY Begins

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content